drugset / Trial / NCT00391534

EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy

NCT00391534

RandomizedParallel-groupOpen-labelTreatment

Summary

This study is intended to investigate the safety and efficacy of a novel formulation of oxcarbazepine that is released more slowly than the current formulation. The study medication will be used as a treatment against partial epilepsy.

Timeline

Start
2006-10
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Oxcarbazepine Small molecule 1200 mg
Comparator Oxcarbazepine Small molecule 1500 mg
Comparator Oxcarbazepine Small molecule 1800 mg
Comparator Oxcarbazepine Small molecule 2100 mg
Comparator Oxcarbazepine Small molecule 2400 mg
Comparator Oxcarbazepine Small molecule 2700 mg

Indications